Kamada (KMDA) Short-term Investments (2012 - 2026)
Kamada's (KMDA) quarterly Short-term Investments came in at $40.7 million in Q2 2026, up 1.08% quarter-over-quarter from $40.2 million in Q1 2026.
Analysis
Kamada (KMDA) Short-term Investments (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Short-term Investments for 15 consecutive years, with $40.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Short-term Investments changed N/A year-over-year to $40.7 million; the trailing twelve-month figure through Jun 2026 stood at $40.7 million (changed N/A YoY), and the FY2025 full-year result was $75.5 million, down 3.78% from the prior year.
- Short-term Investments climbed to $40.7 million in Q2 2026 per KMDA's latest filing, from $40.2 million in the prior quarter.
- Across five years, Short-term Investments topped out at $78.4 million in Q4 2024 and bottomed at $2.8 million in Q4 2022.
- Historically, Short-term Investments has averaged $48.9 million across 5 years, with a median of $48.2 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Short-term Investments plunged 97.75% in 2022, then surged 1854.37% in 2023.
- Over 5 years, Short-term Investments stood at $2.8 million in 2022, then soared by 1854.37% to $55.6 million in 2023, then soared by 40.97% to $78.4 million in 2024, then declined by 3.78% to $75.5 million in 2025, then tumbled by 46.12% to $40.7 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $40.7 million, $40.2 million, and $75.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.66 Mn |
| Mar 31, 2026 | 40.23 Mn |
| Dec 31, 2025 | 75.47 Mn |
| Dec 31, 2024 | 78.44 Mn |
| Dec 31, 2023 | 55.64 Mn |
| Dec 31, 2022 | 2.85 Mn |
| Dec 31, 2021 | 126.71 Mn |
| Jun 30, 2021 | 36.14 Mn |
| Mar 31, 2021 | 48.04 Mn |
| Dec 31, 2020 | 39.07 Mn |
| Sep 30, 2020 | 47.23 Mn |
| Jun 30, 2020 | 47.27 Mn |
| Mar 31, 2020 | 47.12 Mn |
| Dec 31, 2019 | 31.25 Mn |
| Sep 30, 2019 | 39.38 Mn |
| Jun 30, 2019 | 38.12 Mn |
| Mar 31, 2019 | 33.80 Mn |
| Dec 31, 2018 | 32.50 Mn |
| Sep 30, 2018 | 32.05 Mn |
| Jun 30, 2018 | 32.23 Mn |